Last year I focused on immunotherapy drug success stories coming out of the American Society of Clinical Oncology (ASCO) meetings in Chicago.  Immunotherapies dominated the landscape at this year’s meetings, too.

I wrote aposts about it on my daily site:

ASCO kicks-off with a bang! Immunotherapies continue to  impress against a number of different cancers

Here’s an excerpt from the opening of a short (for the NY Times), definitive update I saved about immunotherapy advances made for melanoma, colon cancer and leukemia:

Promising New Cancer Drugs Empower the Body’s Own Defense System

CHICAGO — The early success of a new class of cancer drugs, revealed in test results released here over the last several days, has raised hope among the world’s top cancer specialists that they may be on the verge of an important milestone in the fight against the disease.

The excitement has spread to Wall Street. Shares of Merck and Bristol-Myers Squibb, which are developing such drugs, rose more than 3 percent on Monday after data from their studies was presented over the weekend at the meeting of the American Society of Clinical Oncology.

The drugs, still generally in early testing, work in an entirely new way, by unleashing the immune system to attack cancer cells much as it attacks bacteria. That could be an alternative to often-debilitating chemotherapy.

Finding ways to use the body’s own defenses has been a goal since the late 1800s, when a New York surgeon named William B. Coley noticed that cancer disappeared in a patient who had a severe bacterial infection.

He then began injecting bacteria into cancer patients to rev up their immune systems. His claims of success were disputed and most attempts since then to harness the immune system have not worked.

The new drugs work by disabling a brake on the immune system called the programmed death 1 receptor, or PD-1. And although the data presented at the meeting was from the earliest stage of testing only, the drugs were the center of attention here, with some doctors predicting that cancer treatment was about to shift.

“If you look five years out, most of this meeting will be about immunotherapy,” said Dr. Mario Sznol, a professor of medical oncology at Yale..

Mr. Pollack always does a good job breaking complex issues like this down.  Here’s the link to the rest of his article:

Looks promising!  Could take decades to get all of this sorted-out.  Hope I live long enough to see it!

Feel good and keep smiling!  Pat

Leave a Reply